Recent findings highlight the prognostic utility of IL-18 when evaluated alongside NFL, reinforcing the value of multimodal inflammatory signatures (ALS Therapy Development Institute; Jiang et al., 2022). The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.